NEONC TECHNOLOGIES HOLDINGS, INC. — Form 8-K
Filed August 13, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
NeOnc reported Phase 2a results for NEO100 (intranasal perillyl alcohol) in recurrent IDH1-mutant high-grade glioma: 24 patients (21 Grade IV, 3 Grade III), 48.9% progression-free survival at 6 months (vs. 20% benchmark, p=0.0047), median overall survival 26.1 months from recurrence (vs. historical 6–9 months salvage benchmark), 60.9% alive at 12 months. Company plans FDA Type B meeting to discuss accelerated approval Phase 3 design with OS as primary endpoint.
Why this rating
Early-stage biotech ($67.9M cap); Phase 2a positive data on lead asset is material but Phase 3 and regulatory approval remain uncertain. 4–5× OS improvement is clinically significant, but single-arm 24-patient trial vs. historical benchmarks carries execution risk. Meaningful fraction of market cap depends on Phase 3 success.
See more from August 13, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.